Teva Pharmaceutical Industries Limited Announces Positive Results from a Study Assessing a New Formulation of Copaxone(R)

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced positive results from a study assessing a new lower-volume injection of Copaxone® (glatiramer acetate) containing the currently approved dose in half the injection volume.
MORE ON THIS TOPIC